Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 4Myelodysplastic Syndromes 3Lymphoma 3Leukemia 3Hematologic Neoplasms 2Neoplasms, Plasma Cell 1Hodgkin Disease 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Lenalidomide 11Dexamethasone 11fludarabine 9Cyclophosphamide 7Bortezomib 6fludarabine phosphate 5Melphalan 5pomalidomide 4isatuximab 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Busulfan 3dacetuzumab 2Whole-Body Irradiation 2Thiotepa 2Stem Cell Transplantation 2Leukapheresis 2KW-2478 2Granulocyte Colony-Stimulating Factor 2Cyclosporine 2Calcium Dobesilate 2tanespimycin 1spartalizumab 1sargramostim 1ricolinostat 1pirtobrutinib 1pembrolizumab 1nirogacestat 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × AP 1903 reagent × Plasma cell × Clear all
NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡